The Latest Cardiac and Vascular News
ST. LOUIS PARK, Minn., Sept. 04, 2018 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, today announced that it has successfully treated the first patients in Asia using the NeoChord procedure at Queen […]
TEL AVIV, ISRAEL, Sept. 04, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced it will be presenting at the H.C. Wainwright 20th Annual […]
SHANGHAI, Sept. 3, 2018 /PRNewswire/ — MicroPort Scientific Corporation (“MicroPort®”, HK:0853) announced today that the clinical trial results for its Firehawk® Rapamycin Target Eluting Coronary Stent System (“Firehawk®”) which conducted a multi-center, randomized controlled trial called TARGET AC has been published online in The Lancet, a world leading medical journal currently ranked second […]
SOUTHLAKE, Texas–(BUSINESS WIRE)–Silicon Review, a leading Business and Technology magazine has named HeartSciences, as one of the 50 Smartest Companies of the Year 2018. “The Silicon Review 50 Smartest Companies of the Year 2018 program identifies companies that mastered the discipline of smartness and stood high among the crowd,” said Sreshtha Banerjee, Editor-in-Chief […]
AWANS, Belgium, Sept. 4, 2018 /PRNewswire/ — Miracor Medical SA (Miracor Medical) today announced the final closing of the Series D financing round of €30M. The Series D capital will be used to further develop and commercialize the PiCSO® Impulse System. The Series-D round was led by Ming Capital (Shenzhen, China) and co-led by a […]
CALGARY, Alberta, Aug. 30, 2018 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today it has closed a private placement of approximately 10.4 million equity units at a price of $2.50 per unit for gross proceeds of approximately $26 million (US$20 million), based on an agreed discount […]
MONTRÉAL, Aug. 29, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ:ACST) (TSX-V:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced that the following individuals were elected as directors of Acasti Pharma Inc. (“Acasti” […]
BASKING RIDGE, N.J., Aug. 30, 2018 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius Biosciences, will present a […]
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that senior company management will be participating in the following upcoming investor conferences: 2018 Wells Fargo Healthcare Conference in Boston, MA on Wednesday, […]
GORDON, Australia, Aug. 29, 2018 /PRNewswire/ — The American offshoot of Australian biotech Noxopharm, Nyrada, believes it is within reach of achieving a major advance in the treatment of cardiovascular disease. It has made important progress with a drug candidate known as NYX-330 that Nyrada believes may be the next breakthrough medication for […]
